Clinical efficacy of gemcitabine combined with nedaplatin in treatment of recurrent cervical cancer

Objective To explore the efficacy and safety of Gemcitabine combined with Nedaplatin in the treatment of recurrent cervical cancer Methods Recurrent cervical cancer patients(98 cases) who came to the Sixth Affiliated People's Hospital of Shanghai Jiao Tong University from February 2012 to January 2014 were randomly divided into treatment and control groups(n = 49) by the method of simple random sampling. The patients in the treatment group were given Gemcitabine for iv injection(1 g/m2) by adding in 0.9% normal saline(100 mL), slowly dripping for 30 min, and used on day 1 of the fore three weeks in each chemotherapy cycle. They were injected with Nedaplatin for iv injection(80 mg/m2) by adding in 0.9% normal saline(500 mL), slowly dripping for 60 min, and used on day 1 of the first week in each chemotherapy cycle. The patients in the control group were treated with Gemcitabine for iv injection, and the usage and dosage were the same as those in the treatment group. They were iv injected with Cisplatin for(30 mg/m2) by adding in 0.9% normal saline(30 mL) used on fore 3 d of the first week in each chemotherapy cycle. One course was 28 d in both groups and all the patients accepted the treatment for 2 courses at least. Efficacy and side effects of the two groups were compared after the treatment. Results The effective rates in the treatment and control groups were 63.27% and 55.10%, without significant differences. On adverse reactions, there were no significant differences between the two groups in hair loss, reduced leukopenia, cardiac toxicity, pulmonary toxicity, liver damage, and skin rash. The incidence of reduced platelets in the treatment group was higher than that in the control group, but incidence of nausea, vomiting, reduced hemoglobin, and kidney damage was significantly lower than those in the control group with significant difference(P 0.05). Conclusion There is no difference between Gemcitabine combined with Nedaplatin or Cisplatin in the treatment of recurrent cervical cancer, but the main side effects are small, which could help the patients reduce the pain and improve the chemotherapy compliance.